Skip to content
Trial Eligibility
Menu

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290

This study is recruiting at 17 US sites in 14 states, according to its ClinicalTrials.gov record last updated .

Summary

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Squamous Lung Cancer
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Lung Cancer
  • NSCLC
  • Advanced Lung Carcinoma
  • Epidermal Growth Factor Receptor C797S
  • Epidermal Growth Factor Receptor G719X
  • EGF-R Positive Non-Small Cell Lung Cancer
  • EGFR-TKI Resistant Mutation

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1/2
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Black Diamond Therapeutics, Inc.
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Alabama · 1

  • University of Alabama · Birmingham, AL

Arizona · 1

  • Banner MD Anderson Cancer Center · Gilbert, AZ

California · 2

  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, CA
  • Cedars Sinai Medical Center · Los Angeles, CA

District of Columbia · 1

  • Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C., DC

Florida · 2

  • Mayo Clinic- Jacksonville · Jacksonville, FL
  • Miami Cancer Institute - Baptist Health South Florida · Miami, FL

Hawaii · 1

  • UHP- University of Hawaii Cancer Center · Honolulu, HI

Illinois · 1

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago, IL

Massachusetts · 1

  • Dana-Farber Cancer Institute · Boston, MA

Minnesota · 1

  • Mayo Clinic- Rochester · Rochester, MN

New York · 1

  • Montefiore Medical Center · The Bronx, NY

Pennsylvania · 1

  • University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh, PA

Tennessee · 1

  • Tennessee Oncology · Nashville, TN

Virginia · 2

  • Inova Schar Cancer Institute · Fairfax, VA
  • Next Oncology · Fairfax, VA

Washington · 1

  • Fred Hutchinson Cancer Center/University of Washington · Seattle, WA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.